NCT03059797已完成2 期
A Randomized, Double-blind, Placebo-controlled, Multicenter Clinical Trial to Compare the Efficacy and Safety of Anlotinib Versus Placebo in Patients With Small Cell Lung Cancer(ALTER1202)
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 120
- 试验地点
- 12
- 主要终点
- Progress free survival (PFS)
研究概览
简要总结
To compare the effects and safety of Anlotinib with placebo in patients with small cell lung cancer(SCLC).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histological documentation of small cell lung cancer
- •Advanced small cell lung cancer who had at least two chemotherapy regimens,at least one measurable lesion (by RECIST1.1)
- •18-75 years,ECOG PS:0-2,Life expectancy of more than 3 months
- •Main organs function is normal
- •Women of childbearing potential should agree to use and utilize an adequate method of contraception (such as intrauterine device，contraceptive and condom) throughout treatment and for at least 6 months after study is stopped；the result of serum or urine pregnancy test should be negative within 7 days prior to study enrollment，and the patients required to be non-lactating；Man participants should agree to use and utilize an adequate method of contraception throughout treatment and for at least 6 months after study is stopped
- •Patients should participate in the study voluntarily and sign informed consent
排除标准
- •Patients who have been used anlotinib
- •Patients who have been used targeted drugs(such as sunitinib,bevacizumab,endostar),Immune targeted drugs
- •4 weeks or less from the last cytotoxic therapy, radiation therapy or surgery
- •Patients whose primary lesion with active bleeding within 4 months
- •Carcinomatous meningitis
- •Patients who known to the central nervous system
- •Patients with factors that could affect oral medication (such as dysphagia，chronic diarrhea, intestinal obstruction etc.)
- •Patients with any severe and/or unable to control diseases，including：
- •Blood pressure unable to be controlled ideally(systolic pressure≥150 mmHg，diastolic pressure≥100 mmHg);
- •Patients with Grade 1 or higher myocardial ischemia, myocardial infarction or malignant arrhythmias(including QTc≥450ms(male),QTc≥470ms（female）) and patients with Grade 1 or higher congestive heart failure (NYHA Classification);
- •Patients with active or unable to control serious infections;
- •Patients with cirrhosis, decompensated liver disease, or active hepatitis;
- •Patients with poorly controlled diabetes (fasting blood glucose(FBG)>10mmol/L)
- •Urine protein ≥ ++，and 24-hour urinary protein excretion>1.0 g confirmed;
- •Patients with non-healing wounds or fractures
- •Patients with arterial or venous thromboembolic events occurred within 6 months, such as cerebrovascular accident (including transient ischemic attack), deep vein thrombosis and pulmonary embolism
- •Patients with drug abuse history and unable to get rid of or Patients with mental disorders
- •Imaging showed tumors have involved important blood vessels or by investigators determine likely during the follow-up study and cause fatal hemorrhage
- •History of immunodeficiency
- •Patients with concomitant diseases which could seriously endanger their own safety or could affect completion of the study according to investigators' judgment
研究组 & 干预措施
Anlotinib
Experimental
Anlotinib Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle
干预措施: Anlotinib (Drug)
Placebo
Placebo Comparator
Placebo Day 1 to day 14 followed by 7 days off treatment in a 21-day cycle
干预措施: Placebo (Drug)
结局指标
主要结局
Progress free survival (PFS)
时间窗: From randomization，each 42 days up to PD or death(up to 24 months)
次要结局
- Overall Survival (OS)(From randomization until death (up to 24 months))
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability(Until 30 day safety follow-up visit (up to 24 months))
- Objective Response Rate (ORR)(each 42 days up to intolerance the toxicity or PD (up to 24 months))
- Disease Control Rate (DCR)(each 42 days up to intolerance the toxicity or PD (up to 24 months))
研究者
研究点 (12)
Loading locations...
相似试验
Unknown
2 期
Study of Anlotinib in Patients With Differentiated Thyroid Cancer(ALTER01032)Differentiated Thyroid CancerNCT02586337Chia Tai Tianqing Pharmaceutical Group Co., Ltd.113
Unknown
2 期
Study of Anlotinib in Patients With Gastric Cancer(ALTER0503)Gastric CancerNCT02461407Chia Tai Tianqing Pharmaceutical Group Co., Ltd.378
已完成
2 期
Study of Anlotinib in Patients With Metastatic Colorectal Cancer（mCRC）(ALTER0703)Metastatic Colorectal CancerNCT02332499Chia Tai Tianqing Pharmaceutical Group Co., Ltd.419
Unknown
2 期
Study of Anlotinib in Patients With Soft Tissue Sarcoma（STS）(ALTER0203)Soft Tissue SarcomaNCT02449343Chia Tai Tianqing Pharmaceutical Group Co., Ltd.233
已完成
2 期
Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031)Medullary Thyroid CarcinomaNCT02586350Chia Tai Tianqing Pharmaceutical Group Co., Ltd.91